Adoptive cellular therapies in hematology and oncology

作者：Thomas S; Hauptrock B; Theobald M; Herr W^*

来源：Onkologe, 2012, 18(9): 788-+.

DOI：10.1007/s00761-012-2256-4

• Hematopoietic stem cell transplantation
• Graft-versus-leukemia
• Graft-versus-host disease
• T-cell receptor
• Chimeric antigen receptor

The increasing knowledge on the molecular basis of lymphocyte-mediated rejection of malignant cells allows the development of new adoptive lymphocyte therapies in hematology and oncology. The most important cellular immunotherapy to date is allogeneic hematopoietic stem cell transplantation. The curative effect of this frequently used therapy in leukemia and lymphoma patients is mediated by donor lymphocytes adoptively transferred during transplantation. However, this graft-versus-leukemia effect is typically associated with graft-versus-host reactivity that can induce significant morbidity and mortality. New in vitro methods have been developed that modify donor lymphocytes with the aim of separating both effects. In addition to allogeneic cellular immunotherapy, several treatment approaches using autologous lymphocytes have recently been introduced and the genetic reprogramming of T lymphocytes with antigen-specific receptors is considered to be one of the most promising technologies. This article gives an overview of adoptive cellular therapies in hematology and oncology and discusses the potential of these approaches for the future.

• 出版日期2012-9